The invention concerns a DNA coding a eukaryotic highly active alkaline phosphatase with a specific activity of more than 3000 U/mg. The invention also concerns a process for the production of a DNA according to the invention, a vector containing the DNA according to the invention and a cell line containing this vector. Furthermore the invention concerns a recombinant highly active alkaline phosphatase with a specific activity of more than 3000 U/mg which is coded by the DNA according to the invention.

Description

10 parts

›The invention concerns a DNA coding a eukaryotic…

The invention concerns a DNA coding a eukaryotic highly active alkaline phosphatase with a specific activity of more than 3000 U/mg. Furthermore the invention concerns a process for the production of the DNA according to the invention as well as a vector containing the DNA according to the invention as well as a cell line containing this vector. The invention additionally concerns a recombinant highly active alkaline phosphatase with a specific activity of more than 3000 U/mg which is coded by the DNA according to the invention.

Alkaline phosphatases (AP) are dimeric, zinc-containing, non-specific phosphomonoesterases which are found in all organisms from E. coli to mammals (McComb et al., 1979). Comparison of the primary structure of different alkaline phosphatases showed a high degree of homology (25-30% homology between E. coli and mammalian AP) (Millán, 1988; Harris, 1989).

In humans and higher animals the AP family consists of four members which are coded on different gene loci (Millán, 1988; Harris, 1989). The alkaline phosphatase family includes the tissue-specific APs (placental AP (PLAP), germ cell AP (GCAP) and intestinal AP (IAP)) and the non-tissue-specific APs (TNAP) which are mainly located in the liver, kidney and bones.

A decisive property of the previously known APs is the large variability of the catalytic activity of the mammalian APs which have a 10-100-fold higher specific activity than E. coli AP. Among the mammalian APs the AP from the bovine intestine (bIAP) exhibits the highest specific activity. This property makes the bIAP attractive for biotechnological applications such as enzyme conjugates for a diagnostic reagent or dephosphorylation of DNA. In 1985 Besman and Coleman proved the existence of two IAP isoenzymes in the bovine intestine, the IAP from the calf intestine and the IAP from the intestine of a mature cow (bIAPs), by amino-terminal sequencing of chromatographically purified AP fractions. A clear difference at the amino terminus was described between the bIAP of the mature cow (LVPVEEED) and the bIAP from calf intestine (LIPAEEEN). In 1993 Weissig et al. achieved an accurate biochemical characterization by cloning a recombinant bIAP (bIAP I) with a specific activity of ca. 3000 U/mg and the N-terminus LVPVEEED. However, bIAPs from calf intestine with specific activities of up to 8000 U/mg are also commercially available (Boehringer Mannheim, Biozyme, Oriental Yeast) which, however, have previously not been further characterized. All attempts at cloning these highly active alkaline phosphatases were unsuccessful. It was therefore not possible to produce a recombinant highly active alkaline phosphatase. However, the possibility of recombinant production is absolutely essential for an economic production of highly active alkaline phosphatase.

Consequently the object of the present invention was to provide highly active alkaline phosphatases by recombinant means which can also be cloned. Highly active within the sense of the present invention means that the alkaline phosphatase according to the invention has an at least 10% increased activity compared to previously known alkaline phosphatases.

The object was achieved according to the invention by the provision of a DNA coding a eukaryotic highly active alkaline phosphatase with a specific activity of more than 3000 U/mg, preferably of at least 3500 U/mg in which the amino acid residue at position 322 is smaller than aspartate. A eukaryotic DNA is preferred within the sense of the present invention. Eukaryotic cDNA is particularly preferred which means a DNA that no longer contains introns. The term “amino acid residue smaller than aspartate” is understood as any amino acid, preferably natural amino acids or amino acids derived therefrom, which has a smaller spatial dimension than the structure of the amino acid aspartate. A DNA according to the invention is preferred in which the amino acid residue 322 is glycine, alanine, threonine, valine or serine. A DNA according to the invention is particularly preferred in which the amino acid residue 322 is glycine or serine. It is quite especially preferred that the amino acid residue 322 is glycine. A DNA according to SEQ ID NO.: 1, 3 and 5 (FIGS. 1 , 3 , 5 ) and the associated amino acid sequence according to SEQ ID NO.: 2, 4 and 6 (FIGS. 2 , 4 , 6 ) are part of the present invention. The present invention also concerns those cDNAs which differ from the afore-mentioned only in that the N-terminus is longer or shorter in comparison to the cDNAs according to SEQ ID NO.: 2, 4 and 6. In such cases the name for position 322 according to SEQ ID NO.: 2, 4 and 6 changes correspondingly. If for example the N-terminus is x amino acids longer or shorter than SEQ ID NO.: 2, 4 and 6, the relevant position 322 is also shifted by x amino acids. SEQ ID NO.: 1 contains the DNA code for the sequence of the highly active bIAPII isoenzyme. The native enzyme was known but not characterized and not possible to clone. Hence the determination of the amino acid sequence of the highly active bIAP II isoenzyme is a subject matter of the present invention. A highly purified fraction with high specific activity from the calf intestine (Boehringer Mannheim) was used to determine the sequence. Peptide maps of the highly active AP were produced by cleavage with the endoproteinases LysC, AspN, GluC, trypsin and chemical cleavage by bromocyanogen. The peptides produced in this manner were separated and isolated by means of reversed phase HPLC. Each peptide was analysed by electrospray mass spectroscopy and sequenced by means of Edman degradation. The sequences obtained in this way were compared with the published sequence of bIAP I (Weissig et al., 1993). As expected the amino terminus of bIAP II has the start sequence LIPAEEEN as described by Besman and Coleman ( J. Biol. Chem . 260, 11190-11193 (1985)). The complete amino acid sequence of bIAP II is shown in SEQ ID NO.: 2 (FIG. 2 ). According to this the bIAP II has a total of 24 amino acid substitutions compared to bIAP I. The number of amino acids in the isolated highly active bIAP II isoenzyme is 480 amino acids. The nucleotide sequence of 1798 bp (FIG. 1) includes a coding region of 514 amino acids. The amino acids that are possible from position 481 to 514 inclusive can vary within wide limits.

›In the following the present invention describes the…

In the following the present invention describes the cloning and complete characterization of two new previously unknown bIAPs (bIAP III and bIAP IV). Northern blot analyses were carried out on RNA samples from different sections of the bovine intestine. A cDNA bank of the probes with the strongest hybridization signal was set up with an oligo dT primer (Stratagene, San Diego, Calif., USA) in the vector IZAP II (Stratagene, San Diego, Calif, USA). The complete bank (1.0×10 6 recombinant clones) was screened with the 1075 bp HindIII fragment of bIAP I which covers a region from exon I to VIII of the bIAP I gene. 65 Clones were isolated and sequenced. In this process two new bIAPs were identified (bIAP III and bIAP IV) whose characterization is described further below and were neither completely homologous to bIAP I nor to bIAP II. The nucleotide sequences of bIAP III and IV are shown in FIGS. 3 and 5. The sequence differences of bIAPs I IV are shown in FIG. 7 . However, none of the new bIAPs has the expected N-terminus LIPAEEEN but rather new previously not described N-termini (see FIG. 7 ). The cDNA of the two new bIAP isoenzymes was recleaved with appropriate restriction enzymes and inserted by ligation into the CHO expression vector pcDNA-3 (e.g. from the Invitrogen Co. San Diego, Calif., USA). The clones which contained the new bIAP isoenzymes were brought to expression according to the method described by Invitrogen and the isoenzymes were characterized. The expression of a bIAP gene in various hosts is described in WO 93/18139 (CHO cells, E. coli , baculovirus system). The methods, vectors and expression systems described in this document are part of the disclosure of the present application. The present invention in addition concerns the native and recombinant highly active alkaline phosphatases bIAP III and bIAP IV. The alkaline phosphatases according to SEQ ID NO.: 4 and 6 are particularly preferred. CHO cell lines containing the bIAP III and bIAP IV gene were deposited at the DSMZ, “Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH”, Mascheroder Weg 1b, D-38124 Braunschweig (DSM ACC 2349, DSM ACC 2350).

In the following the invention describes the construction of the bIAP II sequence by ligation of mutated and wild-type fragments of bIAP I, III and IV. A series of intermediary intermediate products (L1N8, INT 1, INT 2 and INT 3) was generated by this process which code for functional isoenzymes. In order to construct these intermediary intermediate products a section of the bIAP-cDNA to be modified was cleaved out in each case with appropriate restriction enzymes and replaced by a segment of another bIAP-cDNA containing the desired mutations which possesses compatible ends by digestion with restriction enzymes. Mutations which cannot be introduced by ligation of segments of different bIAP-cDNAs were introduced by site-directed mutagenesis. The mutated fragment was subsequently recleaved with appropriate restriction enzymes and ligated into a like-wise cleaved bIAP-cDNA segment with compatible ends (FIG. 8 ). The mutations introduced in this manner were subsequently checked by restriction analysis and sequencing.

Hence a subject matter of the present invention is a process for the production of the DNA according to the invention characterized in that mutated and wild-type fragments of the DNA of one or several alkaline phosphatases were ligated. Moreover the present invention concerns a cDNA which codes functional isoenzymes and which is formed as intermediate products during the aforementioned process according to the invention. Additionally the present invention concerns a vector containing the cDNA according to the invention.

A further subject matter of the present invention is a cell line containing the vector according to the invention. Suitable cells are for example eukaryotic cells such as CHO, pichia, hansenula or saccharomyces cerevisiae and aspergillus or prokaryotic cells such as E. coli. E. coli , yeast and CHO cells are particularly preferred. Suitable starting vectors for E. coli strains are for example pTE, pTaq, bPL, pBluescript. Suitable E. coli strains are for example XL1-Blue, HB101, RR1 Δ M15, BL21(DE), MC 1000 etc. Suitable pichia vectors are for example pGAPZα and pPICZα (Invitrogen, San Diego, Calif., USA). A suitable vector for CHO cell lines is for example pcDNA-3 (Invitrogen, San Diego, Calif., USA). A CHO cell line containing the bIAP II gene was deposited at the DSMZ, “Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH”, Mascheroder Weg 1b, D-38124 Braunschweig (DSM ACC 2348).

The kinetic characterization of the recombinant bIAP I, II, III and IV isoenzymes showed considerable differences with regard to the catalytic properties (FIG. 9 ). For example bIAP II has a more than 300% increased i.e. more than three-fold higher specific activity (ca. 8600 U/mg) than bIAP I (ca. 2700 U/mg). But also bIAP III and bIAP IV exhibit an approximately 1.8-fold (ca. 4700 U/mg) and about 2.6-fold (>6700 U/mg) higher activity respectively than bIAP I (FIG. 9) which corresponds to a percentage increase of ca. 170% and 250% respectively. Furthermore there was a considerable measurable difference in the heat stability of the isoenzymes. bIAP I is the most heat stable isoenzyme, the T m value of bIAP II and III is 7° C. lower and the T m value of bIAP IV is 13° C. lower than bIAP I (FIG. 9 ). The T m value is understood as the temperature at which a 50% residual activity is measured after an incubation period of 10 minutes.

In the following the invention describes the identification of amino acid residues which influence the specific activity of the bIAPs. This was aided by the intermediary intermediate products. The expression of the intermediary chimers L1N8, INT 1, INT2 and INT3 enabled 11 of the 24 amino acids to be excluded as an effector for the increase in activity (FIG. 7 ).

The L1N8 mutant enzyme had a comparable specific activity to bIAP I; consequently the mutations V2I, V4A and D8N introduced in this case are not relevant for the increase in the specific activity. The notation V2I means that at position 2 the amino acid valine is replaced by isoleucine.

›The INT 1 mutant has a comparable specific…

The INT 1 mutant has a comparable specific activity to bIAP II and consequently this region is important.

The INT 2 mutant has a comparable specific activity to INT 1 and bIAP II and consequently the mutations S380G, D411G, D416E, Q420R, Q427L, E453Q and T480A from INT 2 can also be excluded.

In generating the INT 3 mutants no change in the high specific activity was found thus excluding an effect of the mutation N192Y.

In order to identify which of the 13 remaining residues are crucial for the high specific activity, the bIAP II cDNA was used in the present invention as a template for single mutations against the corresponding amino acid of bIAP I. The single mutants N122K, I133M, A142S, K180M, M205K, E210V, E236A, G322D and I332G as well as a combined A289Q-A294V-Q297R-L299V bIAP II mutant were constructed (FIG. 9 ).

Surprisingly it was found that mainly the mutation G322D is able to decrease the high specific activity of bIAP II (ca. 8600 U/mg) by more than a factor of 3 (2817 U/mg) and thus to convert it into the comparably low specific activity of bIAP I.

In order to verify this result the reverse mutation D322G was introduced into bIAP I in the present invention. Surprisingly in this case the reverse effect namely an increase of the specific activity of more than 3-fold to 10148 U/mg was measured and hence a comparable value to bIAP II was achieved (FIG. 9 ). A comparison of the amino acid sequences of the relatively more highly active bIAP III (ca. 4700 U/mg) and the more highly active bIAP IV (>6700 U/mg) again confirm this result. bIAP III has a serine at position in 322 and bIAP IV has a glycine.

In addition in the present invention the generated mutants were in turn examined for heat stability. Consequently the difference in the heat stability between bIAP I and bIAP II is due to a combined effect of more than one substitution. The [G 322 ]bIAP I as well as the [D 322 ]bIAP II mutants exhibit stability values which lie between those of the bIAP I and bIAP II isoenzymes (FIG. 9 ). The D322G mutation has a slight destabilizing effect (almost 4° C. in T 50 ) on the bIAP I isoenzyme whereas the substitution G322D in bIAP II results in a corresponding increase in the stability of this mutant enzyme. However, the heat stability of the wild-type bIAP I is not achieved.

Hence the subject matter of the present invention is in particular to provide a highly active recombinant alkaline phosphatase with an activity of more than 3000 U/mg which is coded by a eukaryotic cDNA. A highly active recombinant alkaline phosphatase according to the invention is particularly preferred in which a glycine, alanine, threonine, valine or serine is at position 322. An alkaline phosphatase according to the invention is particularly preferred in which a glycine is at position 322.

The highly active recombinant alkaline phosphatase according to the invention can preferably additionally have a mutation at one or several of the following positions:

Amino acid residues at position 1, 108, 125, 149, 181, 188, 219, 221, 222, 223, 224, 231, 252, 258, 260, 282, 304, 321, 330, 331, 354, 383, 385, 400, 405, 413, 428, 431 and 461 in which the mutation causes an increase in activity. Furthermore the present invention concerns a process for the production of the highly active alkaline phosphatase according to the invention. The alkaline phosphatases according to the invention can also be further improved by specific mutagenesis e.g. with regard to their thermostability.

The activity of the highly active alkaline phosphatase according to the invention was determined according to E. Mössner et al., Z. Physiol. Chem. 361 (1980), 543-549; with the difference that the test was carried out at 37° C. rather than at 25° C. as described in the publication. The determination at 37° C. is the world-wide usual temperature at which the activity is measured in diethanol buffer (BM test method 5426).

The protein determination of the APs according to the invention and of the known APs is carried out by measuring the absorbance of the protein solution at 280 nm against water. The absorbance of a low and highly active AP solution at a concentration of 1 mg/ml is 1.0 at 280 nm (A 280 nm (1 mg/ml) equals 1).

The specific activity is determined by forming a quotient of activity relative to the accompanying amount of protein.

FIGURE LEGENDS

FIG. 1 :

SEQ ID NO.: 1 nucleotide sequence of bIAP II (1798 bp) Start of the coding region for mature bIAP II at pos. 108, end at pos. 1649

FIG. 2 :

SEQ ID NO.: 2 amino acid sequence of bIAP II (480 amino acids) with cleavage sites

FIG. 3 :

SEQ ID NO.: 3 nucleotide sequence of bIAP III (2460 bp) Start of the coding region for mature bIAP III at pos. 123, end at pos. 1655

FIG. 4 :

SEQ ID NO.: 4 amino acid sequence of bIAP III (511-amino acids)

FIG. 5 :

SEQ ID NO.: 5 nucleotide sequence of bIAP IV (2542 bp) Start of the coding region for mature bIAP IV at pos. 122, end at pos. 1654

FIG. 6 :

SEQ ID NO.: 6 amino acid sequence of bIAP IV (511 amino acids)

FIG. 7 :

Amino acid differences between bIAP I, bIAP II, bIAP III and bIAP IV isoenzymes. Only the residues that are different are shown. The asterisk identifies those positions that were selected for individual mutagenesis in order to identify residues that are responsible for an increased catalytic activity of bIAP II.

FIG. 8 :

Ligation strategy for bIAP II DNA

FIG. 9 :

Kinetic parameters and heat stability of recombinant wild-type and chimeric bIAP enzymes and mutants of the bIAP enzymes changed by site-directed mutagenesis. *[QVRV]bIAP II is the abbreviation for the [Q 289 , V 294 , R 297 , V 299 ]bIAP II mutant.

The invention is further elucidated by the following examples:

›Examples7

›Example 1

Cloning

A λgt 11 cDNA bank prepared from the intestine of mature cows (Clontech Laboratories, Palo Alto, Calif., USA) was screened using a 1075 bp Hind III fragment from the 5′ end of the bIAP I cDNA as a probe (Weissig et al., 1993). Clones from this cDNA bank were used to screen an EMBL-3 SP6/T7 genomic cDNA bank which was prepared from the liver of mature cows (Clontech Laboratories, Palo Alto, Calif., USA). A non-amplified λZAP II c-DNA bank was set up by means of an oligo dT primer (Stratagene, San Diego, Calif., USA) from mRNA which was isolated from the small intestine of a mature cow using the Trisolv™ reagent and was screened with the 1075 bp HindIII fragment of the bIAP I cDNA as a probe. The probes were radio-labelled using a random primed DNA labeling kit (Boehringer Mannheim). Phage DNA was prepared as described for λgt 11 and EMBL-3 SP6/T7 clones (Tsonis & Manes, 1988). The in vivo cleavage of the λZAP II clones was carried out according to the manufacturer's instructions (Stratagene, San Diego, Calif.). Genomic clones were characterized by Southern blot analysis as described (Sambrook et al., 1989). EcoRI cDNA fragments of λgt 11 clones and different restriction fragments from clones of other banks were subcloned into the KS+vector (Stratagene, San Diego, Calif., USA). Plasmid DNA was prepared by alkaline lysis (Sambrook et al., 1989). The sequencing was carried out using Sequenase according to the manufacturer's protocol (Amersham). The oligo-nucleotides used to sequence the bIAPs III and IV are described in the following: 1s: SEQ ID NO.7: GCC AAG AAT GTC ATC CTC; 1a: SEQ ID NO.8: GAG GAT GAC ATT CTT GGC; 2s: SEQ ID NO.9: GGT GTA AGT GCA GCC GC; 2a: SEQ ID NO.10: GCG GCT GCA CTT AGA CC; 3s: SEQ ID NO. 11: AAT GTA CAT GTT TCC TG; 3a: SEQ ID NO.12: CAG GAA ACA TGT ACA TT; 4s: SEQ ID NO.13: CCA GGG CTT CTA CCT CTT; 4a: SEQ ID NO.14: AAG AGG TAG AAG CCC TGG; 5s: SEQ ID NO.15: ACC AGA GCT ACC ACC TCG; 5a: SEQ ID NO.16: AAG CAG GAA ACC CCA AGA; 6s: SEQ ID NO.17: CTT CAG TGG CTT GGG ATT; 6a: SEQ ID NO.18: AAT CCC AAG CCA CTG AAG. The nucleic acid sequences were analysed with the MacVector sequence analysis program (International Biotechnologies, Inc. New Haven, Conn., USA).

›Example 2

Determination of the amino acid sequence of bIAP II

Approximately 500 μg of a purified highly active (ca. 6000 U/mg) bovine intestinal AP was dissolved in 450 μl 6M guanidine hydrochloride, 0.25 M Tris, 1 mM EDTA, pH 8.5 and subsequently 30 μl mercaptoethanol was added. After reduction for 30 minutes at 100° C., the cysteines were alkylated by addition of 35 μl vinylpyridine and this mixture was incubated in the dark for 45 minutes at room temperature. The reaction mixture was then immediately desalted over a short reversed phase HPLC Aquapore RP300 column (30×2.1 mm, Applied Biosystems, Weiterstadt). A step gradient of acetonitrile in 0.1% trifluoroacetic acid was used to elute bound enzymes. Fractions containing protein were evaporated to dryness. In order to deglycosylate the enzyme 125 μg AP was dissolved in 15 μl distilled water and 6 μl incubation buffer (250 mM Na 2 HPO 4 , 50 mM EDTA, pH 7.2) and 15 U EndoF/PNGase (Boehringer Mannheim, Penzberg). The mixture was kept overnight at 37° C. and subsequently used for cleavage. Reduced and alkylated AP was enzymatically cleaved with various enzymes according to the instructions on the data sheets of the individual enzymes (endoproteinase LysC, endoproteinase AspN, endoproteinase GluC and trypsin (Boehringer Mannheim, Penzberg). Cyanogen bromide cleavage was carried out for 8 hours using 10% (w/w) CNBr in 70% (v/v) formic-acid. After dissolving with water, the volume of the solution was reduced using a SpeedVac concentrator (Savant) and used for a reversed phase HPLC. The C-terminal tryptic peptide was digested for 4 minutes with carboxypeptidase Y (8 ng/μl) and the released peptides were analysed according to the manufacturer's instructions with matrix-supported laser desorption/ionisation mass spectrometry using a Bruker Reflex III instrument. 2,5 Dihydroxybenzoic acid (10 mg/ml) in acetonitrile/water (50/50, v/v) was used as the matrix. Peptides from enzymatic or chemical cleavages were separated by reversed phase HPLC on a LiChrospher C18 selB column 125×2 mm (Merck, Darmstadt) using a 0.1% trifluoroacetic acid/acetonitrile solvent system. The flow rate was 300 μl/min. The eluant was detected by UV monitoring at 206 nm and the fractions were collected manually. The mass determination of the peptides was carried out with an API III electrospray mass spectrometer (PE-Sciex, Langen) according to the manufacturer's instructions. The amino acid sequence was determined with a 492 A protein sequencer (Applied Biosystems, Weiterstadt) according to the manufacturer's instructions.

›Example 3

Preparation of the bIAP II cDNA and bIAP II mutagenesis

In order to prepare a cDNA which codes for bIAP II, wild-type restriction fragments and site-directed mutagenized PCR fragments of the cDNAs bIAP I, III and IV were ligated with one another and the L1N8 (3 fragments) and INT 1 (9 fragments) cDNA intermediate constructs were created. INT 1 and bIAP III then served as a template for the site-directed mutagenesis and fragments from this were assembled to form the complete INT 2 (8 fragments) cDNA. Restriction fragments of INT 2 and site-directed mutagenized fragments of INT 2 were then assembled to form the INT 3 (5 fragments) cDNA and finally to form the bIAP II (4 fragments) cDNA. The site-directed mutagenesis was carried out according to the method of Tomic et al. (1990) using Bsa I (type II s) as the restriction enzyme which cleaves at a distance from its recognition sequence (GGTCTCN1/N5). All PCR products were sequenced in order to verify the absence of secondary mutations. All constructs were confirmed by sequencing and restriction digestion. The sequence of the oligonucleotide primers used to amplify the site-directed mutagenized fragments are as follows: the name of the primer is mentioned first followed by the sequence (positions that indicate the mutations are underlined: KS:SEQ ID NO.19: CGA GGT CGA CGG TAT CG; 1L:SEQ ID NO.20: GCA GGT CTC TCA GCT GGG ATG A G G GTG AGG; 8N:SEQ ID NO.21: GCA GGT CTC AGC TGA GGA GGA A AA CCC CGC; 122:SEQ ID NO.22: GCA GGT CTC TGT TGT GTC GCA CTG GTT; 1s:SEQ ID NO.7: GCC AAG AAT GTC ATC CTC; M133I:SEQ ID NO.23: GGT CTC TTT CTT GGC CCG GTT G AT CAC; S142A:SEQ ID NO.24: GGT CTC AAG AAA GCA GGG AAG G CC GTC; 180:SEQ ID NO.25: GGT CTC GTG CAT CAG CAG GCA GGT CGG C; M180K:SEQ ID NO.26: GGT CTC ATG CAC AGA A GA ATG GCT GCC AG; K205M:SEQ ID NO.27: GGT CTC AAA CAT GTA CAT TCG GCC TCC ACC; V210E:SEQ ID NO.28: GT CTC CAT GTT TCC TGA GGG GAC CCC A; A236E:SEQ ID NO.29: GGT CTC CTG CCA T T C C TG CAC CAG GTT; 236:SEQ ID NO.30: GGT CTC TGG CAG GCC AAG CAC CAG GGA; 289:SEQ ID NO.31: GGT CTC CAG GGT CGG GTC CTT GGT GTG; E289A:SEQ ID NO.32: GGT CTC GAC CCT GG C GGA GAT GAC G; 330:SEQ ID NO.33: GGT CTC CTC AGT CAG TGC CAT ATA; 330E,V332I:SEQ ID NO:34: GGT CTC ACT GA G GCG A TC ATG TTT GAC; XIa:SEQ ID NO.35: TG CAC CAG GTG CGC CTG CGG GCC; N192Y:SEQ ID NO.36: GCC GCA CAG CTG GTC T AC AAC ATG GAT; S380G:SEQ ID NO.37: GCT GTC TAA GGC CTT GC C GGG GGC; N192Y:SEQ ID NO.38: GCC GCA CAG CTG GTC T AC AAC ATG GAT; D411G:SEQ ID NO.39: GGG GGT CTC GCT TGC TG C CAT TAA C: D416E:SEQ ID NO.40: GTT AAT GGT CTC ACA AGC GAG GA A CCC TCG; S428A:SEQ ID NO.41: CCC GTG GGT CTC GCT AG C C CAG GGG CAC; D416E:SEQ ID NO:42: GTT AAT GGT CTC ACA AGC GAG GA A CCC TCG; T480S:SEQ ID NO.43: GAT GCT GGT CTC GGT GG A GGG GGC TGG CAG; 480:SEQ ID NO.44: CTG CCA GGT CTC ACC ACC GCC ACC AGC ATC; SP6:SEQ ID NO.45: CAT ACG ATT TAG GTG ACA CTA TAG; 236:SEQ ID NO.46: GGT CTC TGG CAG GCC AAG CAC CAG GGA; Q304R-:SEQ ID NO.47: GTA GAA GCC CC G GGG GTT CCT GCT; Q304+:SEQ ID NO.48:AGC AGG AAC C CC CGG GGC TTC TAC; E321D:SEQ ID NO.49: TGC CAT ATA AGC TTT GCC G TC ATG GTG. The various PCR reactions are numbered 1-16, the templates are either wild-type cDNAs bIAP I, III or IV or the chimeric constructs INT 1 or INT 2. The oligonucleotide primers (1L in parantheses) are stated above. 1. bIAP IV (KS, 1L); 2. bIAP IV (8N, 122); 3. bIAP III (1S, M133I); 4.bIAP I (S142A, 180); 5. bIAP I (M180K, K205M); 6. bIAP I(V210E, A236E); 7. bIAP I (236, 289); 8. bIAP IV (E289A, 330); 9. bIAP III (330E, V332I, XIa); 10. INT1 (N192Y, S380G); 11. INT1 (N192Y, D411G); 12. bIAP III (D416E, S428A); 13. INT1 (D416E, T480S); 14. INT1 (480, SP6); 15. INT2 (236, Q304R−); 16. INT2 (Q304R+, E321D). The following ligation reactions were carried out in all cases using the pcDNA- 3 (Invitrogen, San Diego, Calif.) expression vector. The fragments are numbered according to the aforementioned PCR reaction numbers or named with the name of the wild-type or the chimeric cDNA followed by the restriction enzymes which were used to form the cohesive terminus of this fragment. L1N8 =pcDNA-3/EcoRI-XbaI+1/EcoRI-BsaI+2/BsaI-BamHI+bIAP I/BamHI-XbaI. INT 1=pcDNA-3/EcoRI-XbaI+L1N8/EcoRI-NcoI+3/NcoI-BsaI+4/BsaI+5/BsaI+6/BsaI+7/BsaI+8/BsaI+9/BsaI-StuI+bIAP I/StuI-XbaI. INT 2 =pcDNA-3/EcoRI-NotI+INT1/EcoRI-PstI+10/PstI-StuI+11/StuI-BsaI+12/BsaI+13/BsaI+14/BsaI+bIAP I/BsaI-NotI. INT 3 =pcDNA-3/EcoRI-XbaI+INT2/EcoRI-NcoI+INT2/NcoI-PvuII+10/PvuII-EagI+INT2/EagI-HindIII+INT2/HindIII-XbaI. bIAP II=pcDNA-3/EcoRI-XbaI+INT3/EcoRI-EagI+15/EagI-SmaI+16/SmaI-HindIII+INT3/HindIII-XbaI.

10 Additional constructs were prepared in order to identify the residue (the residues) which are responsible for the various kinetic properties of bIAP I and II. All constructs were subcloned in pcDNA-3/EcoRI-XbaI. 5 Constructs were prepared by exchange of restriction fragments between L1N8 or bIAP I (I) and bIAP II (II). L1N8 EcoRI-Pm1I and (II) Pm1I-XbaI were ligated in order to prepare the [N122K]bIAP II mutant cDNA. (II) EcoRI-BstEII, (I) BstEII-PvuII, (II) PvuII XbaI were combined for the [K180M]bIAP II mutant cDNA. (II) EcoRI-EagI, (I) EagI-BstEII, (II) BstEII-XbaI were ligated for the [A289Q, A294V, Q297R, L299V]bIAP II mutant. (II) EcoRI-EagI, (II) EagI-BstEII, (I) BstEII-HindIII, (II) HindIII-XbaI for the [G322D]bIAP II mutant. (II) EcoRI-HindIII, (I) HindIII-SacI, (II) SacI-XbaI for the [I332G]bIAP II mutant. 5 other positions required new site-directed mutagenesis. The following oligonucleotides were used for this: I133M-:SEQ ID NO.50: GGT CTC TTT CTT GGC CCG GTT CAT CAC; A142S-:SEQ ID NO.51: TGG TCA CCA CTC CCA CGG ACT TCC CTG; M205K-:SEQ ID NO.52: GGT CTC AAA CAT GTA TTT TCG GCC TCC ACC; E210V+:SEQ ID NO.53: GGT CTC ATG TTT CCT GTG GGG ACC CCA GAC; E236A:SEQ ID NO.54: GGT CTC CTG CCA TGC CTG CAC CAG GTT. The following 8 PCR reactions (a-h) with bIAP II as the template were carried out using these and the previously listed oligonucleotides: a. 1s, I133M−; b. S142A+, M205K−; c. 1s, A142S−; d. V210E+, 330−; e. E210V+, 330−; f. M180K+, E236A−; g. 236+, 330−; h. S142A, K205M−. The products which were formed from this were subcloned and sequenced and then the fragments were isolated for the following ligations: (II) EcoRI-NcoI, (a) NcoI-BsaI, (b) BsaI, PvuII, (II) PvuII-XbaI for I133M. (II) EcoRI-NcoI, (c) NcoI-BstEII, (II) BstEII-PvuII, (II) PvuII-XbaI for A142S. (II) EcoRI-BstEII, (b) BstEII-BsaI, (d) BsaI-HindIII, (II) HindIII-XbaI for M205K. (II) EcoRI-BstEII, (h) BstEII-BsaI, (e) BsaI-HindIII, (II) HindIII-XbaI for E210V. (II) EcoRI-NcoI, (II) NcoI-PvuII, (f) PvuII-BsaI, (g) BsaI-HindIII, (II) HindIII-XbaI for E236A.

›Example 4 · 1 of 4

Production and characterization of recombinant enzymes

All cDNAs (bIAP I, bIAP II, bIAP III, bIAP IV and corresponding mutants) were cloned into the pcDNA-3 expression vector (Invitrogen, San Diego, Calif., USA), transferred into ovarial cells of a chinese hamster (CHO cells) and stable transfectants were selected by growing the cells in the presence of 500 μg/ml geneticin (Gibco, BRL). Recombinant APs were extracted as described from stably transferred CHO cells (Hoylaerts et al., 1997). Microtitre plates that were coated with 0.1 μg/ml high affinity anti-bovine AP monoclonal antibody (Scottish Antibody Production Unit, Lanarkshire, Scotland) were incubated with increasing enzyme concentrations in order to measure the k cat . The activity of the bound enzyme was measured as the change in absorbance with time at 405 nm and 20° C. after addition of 30 mM p-nitrophenyl phosphate (pNPP) as the substrate in 1.0 M diethanolamine buffer (pH 9.8), 1 mM MgCl 2 and 20 μM ZnCl 2 . The concentration of the p-nitrophenol that formed was calculated with an extinction coefficient of 10,080 litre mole −1 cm −1 . Commercial preparations with known specific activities (Biozyme Laboratories, 7822 U/mg and Boehringer Mannheim, 3073 U/mg) and also purified bIAP II (8600 U/mg) were used as standards. The enzyme concentration in these solutions which saturated the antibody (E°) was calculated from a standard curve of activity against known enzyme concentrations under identical test conditions. The maximum substrate conversion (V max ) was then divided by E° in order to calculate k cat . In order to calculate K m the substrate concentration was changed between 0.25-2.0 mM p-nitrophenyl phosphate (pNPP) and the initial reaction rate at 20° C. was measured over a period of 10 minutes. Regression curves of [pNPP]/v versus [pNPP] (Hanes curves) as the X axis yielded −K m . Division of the standard deviation of the calculated y value for each x value in the regression by the slope of regression yielded the standard deviation of K m . V max ±standard deviation was calculated using the appropriate equations by dividing K m ± standard deviation by the y intercept±standard deviation. The specific activities were calculated in comparison to Biozyme on the basis of antibody-saturated activity. Heat stability curves were established by incubation of extracts at 45-75° C. with an increase in 5° C. steps every 10 minutes as described previously (Weissig et al., 1993). The activity of each sample was then determined as described above and the residual activity was calculated as the residual percentage compared to the non-heated sample. The temperature at which 50% residual activity remains (T 50 ) was calculated from the residual activity against temperature curves.

1798 base pairs

nucleotide

single strand

linear

genomic DNA

GAATTCGGCA CGAGCCAGGT CCCATCCTGA CCCTCCGCCA TCACACAGCT ATGCAGTGGG 60

CCTGTGTGCT GCTGCTGCTG GGCCTGTGGC TACAGCTCTC CCTCACCCTC ATCCCAGCTG 120

AGGAGGAAAA CCCCGCCTTC TGGAACCGCC AGGCAGCCCA GGCCCTTGAT GTAGCCAAGA 180

AGTTGCAGCC GATCCAGACA GCTGCCAAGA ATGTCATCCT CTTCTTGGGG GATGGGATGG 240

GGGTGCCTAC GGTGACAGCC ACTCGGATCC TAAAGGGGCA GATGAATGGC AAACTGGGAC 300

CTGAGACACC CCTGGCCATG GACCAGTTCC CATACGTGGC TCTGTCCAAG ACATACAACG 360

TGGACAGACA GGTGCCAGAC AGCGCAGGCA CTGCCACTGC CTACCTGTGT GGGGTCAAGG 420

GCAACTACAG AACCATCGGT GTAAGTGCAG CCGCCCGCTA CAATCAGTGC AACACGACAC 480

GTGGGAATGA GGTCACGTCT GTGATCAACC GGGCCAAGAA AGCAGGGAAG GCCGTGGGAG 540

TGGTGACCAC CACCAGGGTG CAGCATGCCT CCCCAGCCGG GGCCTACGCG CACACGGTGA 600

ACCGAAACTG GTACTCAGAC GCCGACCTGC CTGCTGATGC ACAGAAGAAT GGCTGCCAGG 660

ACATCGCCGC ACAGCTGGTC TACAACATGG ATATTGACGT GATCCTGGGT GGAGGCCGAA 720

TGTACATGTT TCCTGAGGGG ACCCCAGACC CTGAATACCC AGATGATGCC AGTGTGAATG 780

GAGTCCGGAA GGACAAGCAG AACCTGGTGC AGGAATGGCA GGCCAAGCAC CAGGGAGCCC 840

AGTATGTGTG GAACCGCACT GCGCTCCTTC AGGCGGCCGA TGACTCCAGT GTAACACACC 900

TCATGGGCCT CTTTGAGCCG GCAGACATGA AGTATAATGT TCAGCAAGAC CACACCAAGG 960

ACCCGACCCT GGCGGAGATG ACGGAGGCGG CCCTGCAAGT GCTGAGCAGG AACCCCCGGG 1020

GCTTCTACCT CTTCGTGGAG GGAGGCCGCA TTGACCACGG TCACCATGAC GGCAAAGCTT 1080

ATATGGCACT GACTGAGGCG ATCATGTTTG ACAATGCCAT CGCCAAGGCT AACGAGCTCA 1140

CTAGCGAACT GGACACGCTG ATCCTTGTCA CTGCAGACCA CTCCCATGTC TTCTCTTTTG 1200

GTGGCTACAC ACTGCGTGGG ACCTCCATTT TCGGTCTGGC CCCCGGCAAG GCCTTAGACA 1260

GCAAGTCCTA CACCTCCATC CTCTATGGCA ATGGCCCAGG CTATGCGCTT GGCGGGGGCT 1320

CGAGGCCCGA TGTTAATGGC AGCACAAGCG AGGAACCCTC ATACCGGCAG CAGGCGGCCG 1380

TGCCCCTGGC TAGCGAGACC CACGGGGGCG AAGACGTGGC GGTGTTCGCG CGAGGCCCGC 1440

AGGCGCACCT GGTGCACGGC GTGCAGGAGG AGACCTTCGT GGCGCACATC ATGGCCTTTG 1500

CGGGCTGCGT GGAGCCCTAC ACCGACTGCA ATCTGCCAGC CCCCGCCACC GCCACCAGCA 1560

TCCCCGACGC CGCGCACCTG GCGGCCAGCC CGCCTCCACT GGCGCTGCTG GCTGGGGCGA 1620

TGCTGCTGCT GCTGGCGCCC ACCTTGTACT AACCCCCACC AGTTCCAGGT CTCGGGATTT 1680

CCCGCTCTCC TGCCCAAAAC CTCCCAGCTC AGGCCCTACC GGAGCTACCA CCTCAGAGTC 1740

CCCACCCCGA AGTGCTATCC TAGCTGCCAC TCCTGCAGAC CCGACCCAGC CGGAATTC 1798

480 amino acids

amino acid

single strand

linear

protein

Leu Ile Pro Ala Glu Glu Glu Asn Pro Ala Phe Trp Asn Arg Gln Ala

1 5 10 15

Ala Gln Ala Leu Asp Val Ala Lys Lys Leu Gln Pro Ile Gln Thr Ala

20 25 30

Ala Lys Asn Val Ile Leu Phe Leu Gly Asp Gly Met Gly Val Pro Thr

35 40 45

Val Thr Ala Thr Arg Ile Leu Lys Gly Gln Met Asn Gly Lys Leu Gly

50 55 60

Pro Glu Thr Pro Leu Ala Met Asp Gln Phe Pro Tyr Val Ala Leu Ser

65 70 75 80

Lys Thr Tyr Asn Val Asp Arg Gln Val Pro Asp Ser Ala Gly Thr Ala

85 90 95

Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn Tyr Arg Thr Ile Gly Val

100 105 110

Ser Ala Ala Ala Arg Tyr Asn Gln Cys Asn Thr Thr Arg Gly Asn Glu

115 120 125

Val Thr Ser Val Ile Asn Arg Ala Lys Lys Ala Gly Lys Ala Val Gly

130 135 140

Val Val Thr Thr Thr Arg Val Gln His Ala Ser Pro Ala Gly Ala Tyr

145 150 155 160

Ala His Thr Val Asn Arg Asn Trp Tyr Ser Asp Ala Asp Leu Pro Ala

165 170 175

Asp Ala Gln Lys Asn Gly Cys Gln Asp Ile Ala Ala Gln Leu Val Tyr

180 185 190

Asn Met Asp Ile Asp Val Ile Leu Gly Gly Gly Arg Met Tyr Met Phe

195 200 205

Pro Glu Gly Thr Pro Asp Pro Glu Tyr Pro Asp Asp Ala Ser Val Asn

210 215 220

Gly Val Arg Lys Asp Lys Gln Asn Leu Val Gln Glu Trp Gln Ala Lys

›Example 4 · 2 of 4

225 230 235 240

His Gln Gly Ala Gln Tyr Val Trp Asn Arg Thr Ala Leu Leu Gln Ala

245 250 255

Ala Asp Asp Ser Ser Val Thr His Leu Met Gly Leu Phe Glu Pro Ala

260 265 270

Asp Met Lys Tyr Asn Val Gln Gln Asp His Thr Lys Asp Pro Thr Leu

275 280 285

Ala Glu Met Thr Glu Ala Ala Leu Gln Val Leu Ser Arg Asn Pro Arg

290 295 300

Gly Phe Tyr Leu Phe Val Glu Gly Gly Arg Ile Asp His Gly His His

305 310 315 320

Asp Gly Lys Ala Tyr Met Ala Leu Thr Glu Ala Ile Met Phe Asp Asn

325 330 335

Ala Ile Ala Lys Ala Asn Glu Leu Thr Ser Glu Leu Asp Thr Leu Ile

340 345 350

Leu Val Thr Ala Asp His Ser His Val Phe Ser Phe Gly Gly Tyr Thr

355 360 365

Leu Arg Gly Thr Ser Ile Phe Gly Leu Ala Pro Gly Lys Ala Leu Asp

370 375 380

Ser Lys Ser Tyr Thr Ser Ile Leu Tyr Gly Asn Gly Pro Gly Tyr Ala

385 390 395 400

Leu Gly Gly Gly Ser Arg Pro Asp Val Asn Gly Ser Thr Ser Glu Glu

405 410 415

Pro Ser Tyr Arg Gln Gln Ala Ala Val Pro Leu Ala Ser Glu Thr His

420 425 430

Gly Gly Glu Asp Val Ala Val Phe Ala Arg Gly Pro Gln Ala His Leu

435 440 445

Val His Gly Val Gln Glu Glu Thr Phe Val Ala His Ile Met Ala Phe

450 455 460

Ala Gly Cys Val Glu Pro Tyr Thr Asp Cys Asn Leu Pro Ala Pro Ala

465 470 475 480

2460 base pairs

nucleotide

single strand

linear

genomic DNA

GAATTCGGCA CGAGCGAGAC CCAGACTCCC CAGGTCCCAT CCTGACCCTC CGCCATCACA 60

CAGCTATGCA GGGGGCCTGC GTGCTGCTGC TGCTGGGCCT GTGGCTACAG CTCTCCCTCG 120

CCTTCATCCC AGTTGAGGAG GAAGACCCCG CCTTCTGGAA CCGCCAGGCA GCCCAGGCCC 180

TTGATGTGGC TAAGAAGCTG CAGCCCATCC AGAAAGCCGC CAAGAATGTC ATCCTCTTCT 240

TGGGAGATGG GATGGGGGTG CCTACGGTGA CAGCCACTCG GATACTGAAG GGGCAGATGA 300

ATGACAAGCT GGGACCTGAG ACACCCCTGG CCATGGACCA GTTCCCATAC GTGGCTCTGT 360

CCAAGACATA CAACGTGGAC AGACAGGTGC CAGACAGCGC AGGCACTGCC ACTGCCTACC 420

TGTGTGGGGT CAAGGGCAAC TACAGAACCA TCGGTGTAAG TGCAGCCGCC CGCTACAATC 480

AGTGCAACAC GACACGTGGG AATGAGGTCA CGTCTGTGAT GAACCGGGCC AAGAAAGCAG 540

GGAAGTCAGT GGGAGTGGTG ACCACCACCA GGGTGCAGCA CGCCTCCCCA GCCGGTGCTT 600

ATGCACACAC GGTGAACCGT GACTGGTACT CAGACGCCGA CCTGCCTGCC GATGCACAGA 660

CGTATGGCTG CCAGGACATC GCCACACAAC TGGTCAACAA CATGGATATT GACGTGATCC 720

TGGGTGGAGG CCGAAAGTAC ATGTTTCCTG AGGGGACCCC AGACCCTGAA TACCCACACG 780

ATGCCAGTGT GAATGGAGTC CGGAAGGACA AGCGGAATCT GGTGCAGGAG TGGCAGGCCA 840

AGCACCAGGG AGCCCAGTAT GTGTGGAACC GCACGGAGCT CCTTCAGGCA GCCAATGACT 900

CCAGTGTTAC ACATCTCATG GGCCTCTTTG AGCCGGCAGA CATGAAGTAT AATGTTCAGC 960

AAGACCCCAC CAAGGACCCG ACCCTGGAGG AGATGACGGA GGCGGCCCTG CAAGTGCTGA 1020

GCAGGAACCC CCAGGGCTTC TACCTCTTCG TGGAGGGAGG CCGCATTGAC CACGGTCACC 1080

ATGATAGCAA AGCTTATATG GCGCTGACTG AGGCGGTCAT GTTTGACAAT GCCATCGCCA 1140

AGGCTAACGA GCTCACTAGC GAACTGGACA CGCTGATCCT TGTCACTGCA GACCACTCCC 1200

ATGTCTTCTC TTTTGGTGGC TACACACTGC GTGGGACCTC CATTTTCGGT CTGGCCCCCA 1260

GCAAGGCCTC AGACAAGAAG TCCTACACCT CCATCCTCTA TGGCAATGGC CCTGGCTACG 1320

TGCTTGGTGG GGGCTCAAGG CCCGATGTTA ATGACAGCAT AAGCGAGGAC CCCTCATACC 1380

GGCAGCAGGC GGCCGTGCCC CTGTCTAGCG AGACCCACGG GGGCGAAGAC GTGGCGGTGT 1440

TCGCGCGAGG CCCGCAGGCG CACCTGGTGC ACGGCGTGCA GGAGGAGACC TTCGTGGCGC 1500

ACGTCATGGC CTTTGCGGGC TGCGTGGAGC CCTACACCGA CTGCAATCTG CCGGCCCCCT 1560

CTGGCCTCTC CGACGCCGCG CACCTGGCGG CCAGCGCGCC TTCGCTAGCG CTGCTGGCCG 1620

GGGCGATGCT GCTGCTGCTG GCGCCCGCCT TGTACTGACC CCCACCAACT CCAGGTCTTG 1680

GGGTTTCCCG CTTTCTTGCC CCAAAATCTC CCAGCGCAGG CCCCATCTGA GCTACCACCT 1740

CAGAGTCCCC ACCCTGAAGT CCTATCTAGC GCACTCCAGA CCGCGACTCA GCCCCACCAC 1800

CAGAGCTTCA CCTCCCAGCA ACGAAGGAGC CTTAGCTCAC AGCCTTTCAT GGCCCAGACC 1860

ATTCTGGAGA CTGAGGCCCT GATTTTCCCG ACCCAACTTC AGTGGCTTGA GATTTTGTGT 1920

TCTGCCACCC CGGATCCCTG TAAGGGGGCT CGGACCATCC AGACTCCCCC CACTGCCCAC 1980

AGCCGAACCT GAGGACCAGG CTGGCACGGT CCCAGGGGTC CCAGGCCCGG CTGGAACCCA 2040

CATCTTTGCC TTTCAGGAGA CCCTGGGACT GTGGGGTTTC CAGGAGGCGT GGCTTCTTGG 2100

AGGCGTGGCT TCGGAGGGGT GGCTTCCGAG AAGGCGTGGC TCCCTGTCCT GGAACCACCC 2160

TGTGGGNATC TGGGGCCCAA GGAGATGTCT GGGGCAAAGA GTGCCGGGGG ACCCTGGACA 2220

CAGAATCTTC AGCGGCCCCT CCTAGGAACC CAGCAGTACC ATTATAGAGA GGGGACACCG 2280

ACACAGAGGA GAGGAGACTT GTCCCAGGTC CCTCAGCTGC TGTGAGGGGT GACCCTTGGT 2340

TCCCGTTACC AGGCTGGGGG ATCCCAGGAG CAGCGGGGGA CCTGGGGGTG GGGACACAGG 2400

CCCCACACTC CTGGGAGGGA GGAAGCAGCC CTNAAATAAA CTGTTCCTCG TGCCGAATTC 2460

511 amino acids

amino acid

single strand

linear

protein

Phe Ile Pro Val Glu Glu Glu Asp Pro Ala Phe Trp Asn Arg Gln Ala

1 5 10 15

Ala Gln Ala Leu Asp Val Ala Lys Lys Leu Gln Pro Ile Gln Lys Ala

20 25 30

Ala Lys Asn Val Ile Leu Phe Leu Gly Asp Gly Met Gly Val Pro Thr

35 40 45

Val Thr Ala Thr Arg Ile Leu Lys Gly Gln Met Asn Asp Lys Leu Gly

50 55 60

Pro Glu Thr Pro Leu Ala Met Asp Gln Phe Pro Tyr Val Ala Leu Ser

65 70 75 80

Lys Thr Tyr Asn Val Asp Arg Gln Val Pro Asp Ser Ala Gly Thr Ala

85 90 95

Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn Tyr Arg Thr Ile Gly Val

100 105 110

Ser Ala Ala Ala Arg Tyr Asn Gln Cys Asn Thr Thr Arg Gly Asn Glu

115 120 125

Val Thr Ser Val Met Asn Arg Ala Lys Lys Ala Gly Lys Ser Val Gly

130 135 140

Val Val Thr Thr Thr Arg Val Gln His Ala Ser Pro Ala Gly Ala Tyr

145 150 155 160

Ala His Thr Val Asn Arg Asp Trp Tyr Ser Asp Ala Asp Leu Pro Ala

165 170 175

Asp Ala Gln Thr Tyr Gly Cys Gln Asp Ile Ala Thr Gln Leu Val Asn

180 185 190

Asn Met Asp Ile Asp Val Ile Leu Gly Gly Gly Arg Lys Tyr Met Phe

195 200 205

Pro Glu Gly Thr Pro Asp Pro Glu Tyr Pro His Asp Ala Ser Val Asn

210 215 220

Gly Val Arg Lys Asp Lys Arg Asn Leu Val Gln Glu Trp Gln Ala Lys

225 230 235 240

His Gln Gly Ala Gln Tyr Val Trp Asn Arg Thr Glu Leu Leu Gln Ala

245 250 255

Ala Asn Asp Ser Ser Val Thr His Leu Met Gly Leu Phe Glu Pro Ala

260 265 270

Asp Met Lys Tyr Asn Val Gln Gln Asp Pro Thr Lys Asp Pro Thr Leu

275 280 285

Glu Glu Met Thr Glu Ala Ala Leu Gln Val Leu Ser Arg Asn Pro Gln

290 295 300

Gly Phe Tyr Leu Phe Val Glu Gly Gly Arg Ile Asp His Gly His His

305 310 315 320

Asp Ser Lys Ala Tyr Met Ala Leu Thr Glu Ala Val Met Phe Asp Asn

325 330 335

Ala Ile Ala Lys Ala Asn Glu Leu Thr Ser Glu Leu Asp Thr Leu Ile

340 345 350

Leu Val Thr Ala Asp His Ser His Val Phe Ser Phe Gly Gly Tyr Thr

355 360 365

Leu Arg Gly Thr Ser Ile Phe Gly Leu Ala Pro Ser Lys Ala Ser Asp

370 375 380

Lys Lys Ser Tyr Thr Ser Ile Leu Tyr Gly Asn Gly Pro Gly Tyr Val

385 390 395 400

Leu Gly Gly Gly Ser Arg Pro Asp Val Asn Asp Ser Ile Ser Glu Asp

›Example 4 · 3 of 4

405 410 415

Pro Ser Tyr Arg Gln Gln Ala Ala Val Pro Leu Ser Ser Glu Thr His

420 425 430

Gly Gly Glu Asp Val Ala Val Phe Ala Arg Gly Pro Gln Ala His Leu

435 440 445

Val His Gly Val Gln Glu Glu Thr Phe Val Ala His Val Met Ala Phe

450 455 460

Ala Gly Cys Val Glu Pro Tyr Thr Asp Cys Asn Leu Pro Ala Pro Ser

465 470 475 480

Gly Leu Ser Asp Ala Ala His Leu Ala Ala Ser Ala Pro Ser Leu Ala

485 490 495

Leu Leu Ala Gly Ala Met Leu Leu Leu Leu Ala Pro Ala Leu Tyr

500 505 510

2542 base pairs

nucleotide

single strand

linear

genomic DNA

GAATTCGGCA CGAGGAGACC CGGCCTCCCC AGGTCCCATC CTGACCCTCC GCCATCACAC 60

AGCCATGCAG TGGGCCTGTG TGCTGCTGCT GCTGGGCCTG TGGCTACAGC TCTCCCTCAC 120

CTTCATCCCA GCTGAGGAGG AAGACCCCGC CTTCTGGAAC CGCCAGGCAG CCCAGGCCCT 180

TGATGTAGCC AAGAAGTTGC AGCCGATCCA GACAGCTGCC AAGAATGTCA TCCTCTTCTT 240

GGGGGATGGG ATGGGGGTGC CTACGGTGAC AGCCACTCGG ATCCTAAAGG GGCAGATGAA 300

TGGTAAGCTG GGACCTGAGA CACCCCTGGC CATGGACCAG TTCCCATACG TGGCTCTGTC 360

CAAGACATAC AACGTGGACA GACAGGTGCC AGACAGCGCA GGCACTGCCA CTGCCTACCT 420

GTGTGGGGTC AAGGGCAACT ACAAAACCAT TGGTGTAAGT GCAGCCGCCC GCTACAACCA 480

GTGCAACACA ACAAGTGGCA ATGAGGTCAC GTCTGTGATG AACCGGGCCA AGAAAGCAGG 540

AAAGTCAGTG GGAGTGGTGA CCACCTCCAG GGTGCAGCAT GCCTCCCCAG CCGGTGCTTA 600

TGCACACACG GTGAACCGAA ACTGGTACTC AGATGCCGAC CTGCCTGCCG ATGCACAGAC 660

GTATGGCTGC CAGGACATCG CCACACAACT GGTCAACAAC ATGGATATTG ACGTGATCCT 720

GGGTGGAGGC CGAATGTACA TGTTTCCTGA GGGGACCCCG GATCCTGAAT ACCCATACGA 780

TGTCAATCAG ACTGGAGTCC GGAAGGACAA GCGGAATCTG GTGCAGGAGT GGCAGGCCAA 840

GCACCAGGGA GCCCAGTATG TGTGGAACCG CACGGAGCTC CTTCAGGCAG CCAATGACCC 900

CAGTGTAACA CACCTCATGG GCCTCTTTGA GCCGGCAGAC ATGAAGTATA ATGTTCAGCA 960

AGACCCCACC AAGGACCCGA CCCTGGAGGA GATGACGGAG GCGGCCCTGC AAGTGCTGAG 1020

CAGGAACCCC CAGGGCTTCT ACCTCTTCGT GGAGGGAGGC CGCATTGACC ACGGTCACCA 1080

TGAAGGCAAA GCTTATATGG CACTGACTGA TACAGTCATG TTTGACAATG CCATCGCCAA 1140

GGCTAACGAG CTCACTAGCG AACTGGACAC GCTGATCCTT GCCACTGCAG ACCACTCCCA 1200

TGTCTTCTCT TTTGGTGGCT ACACACTGCG TGGGACCTCC ATTTTCGGTC TGGCCCCCAG 1260

CAAGGCCTCA GACAACAAGT CCTACACCTC CATCCTCTAT GGCAATGGCC CTGGCTACGT 1320

GCTTGGTGGG GGCTTAAGGC CCGATGTTAA TGACAGCATA AGCGAGGACC CCTCGTACCG 1380

GCAGCAGGCG GCCGTGCCCC TGTCTAGTGA GTCCCACGGG GGCGAGGACG TGGCGGTGTT 1440

CGCGCGAGGC CCGCAGGCGC ACCTGGTGCA CGGCGTGCAG GAGGAGACCT TCGTGGCGCA 1500

CGTCATGGCC TTTGCGGGCT GCGTGGAGCC CTACACCGAC TGCAATCTGC CGGCCCCCTC 1560

TGGCCTCTCC GACGCCGCGC ACCTGGCGGC CAGCCCGCCT TCGCTGGCGC TGCTGGCCGG 1620

GGCGATGCTG CTGCTGCTGG CGCCTGCCTT GTACTGACCC CCACCAACTC CAGGTCTTGG 1680

GGTTTCCTGC TTTCCTGCCA AAAATCTCCC AGCGCAGACC CCACCAGAGC TACCACCTCG 1740

GAGTCTCCAC CCTGAAGTCC TATCTTAGCG GCCACTCCCG GATCCCCGAC CAGGCCCCAC 1800

TAGCAGAGCT TCACCTCCCA GAAATGAAGG ATTCACCTTC CAGCAACGAA GAAGCCTCAG 1860

CTCACAGCCC TTCATGGCCC AGCCCATCCA GAGGCTGAGG CCCTGATTTC CCTGTGACAC 1920

CCGTAGACCT ACTGCCCGAC CCCAACTTCA GTGGCTTGGG ATTTTGTGTT CTGCCACCCC 1980

TAACCCCAGT AAGGGGGCTC GGACCATCCA GACTCTCCCC ACTGCCCACA ACCCCACCTG 2040

AGAACCAGGC TAGCACGGTC CCAAGGTTCC CAGGCCCGGC TAGAACCCAC ACCATGCCTT 2100

TCAGGAGACC CTGGGGCTCC GGGGTTTCCG GGAGGCGTGG CTTTCTTAGG AGGCGTGGAA 2160

ACTGAGGAGG CACGGTTTCT GAGGAGGCGT GCGTCCTGGG GAGCTGTGGC TTCCGGTCCT 2220

CCCCATGCCC TGTGGGCTCC TCCCTAACCA AGGAGACGGC CAAGGAGACG TCTGGAACCA 2280

GGAGCGGCGG GGGAACCTTG CAGAGCCCTC AGCAACCCCT CCTAGGAACC CAGGGTACCG 2340

TTAGAGAGAG GAGACAGCGA CACAGAGGAG AGGAGACTTG TCCCAGGTCT CTCAGCTGCT 2400

ATGAAGGTGG CCCCGGTGCC CCTTCCAGGC TGGGAGATCC CAGGAGCAGC GGGGGAGCTG 2460

GTGGGTGGGG ACACAGCCCC GCCTTCATGG GAGGGAGGAA GCAGCCCTCA AATAAACTGT 2520

TCTAAGTGTG AAAAAATCTA GA 2542

511 amino acids

amino acid

single strand

linear

protein

Phe Ile Pro Ala Glu Glu Glu Asp Pro Ala Phe Trp Asn Arg Gln Ala

1 5 10 15

Ala Gln Ala Leu Asp Val Ala Lys Lys Leu Gln Pro Ile Gln Thr Ala

20 25 30

Ala Lys Asn Val Ile Leu Phe Leu Gly Asp Gly Met Gly Val Pro Thr

35 40 45

Val Thr Ala Thr Arg Ile Leu Lys Gly Gln Met Asn Gly Lys Leu Gly

50 55 60

Pro Glu Thr Pro Leu Ala Met Asp Gln Phe Pro Tyr Val Ala Leu Ser

65 70 75 80

Lys Thr Tyr Asn Val Asp Arg Gln Val Pro Asp Ser Ala Gly Thr Ala

85 90 95

Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn Tyr Lys Thr Ile Gly Val

100 105 110

Ser Ala Ala Ala Arg Tyr Asn Gln Cys Asn Thr Thr Ser Gly Asn Glu

115 120 125

Val Thr Ser Val Met Asn Arg Ala Lys Lys Ala Gly Lys Ser Val Gly

130 135 140

Val Val Thr Thr Ser Arg Val Gln His Ala Ser Pro Ala Gly Ala Tyr

145 150 155 160

Ala His Thr Val Asn Arg Asn Trp Tyr Ser Asp Ala Asp Leu Pro Ala

165 170 175

Asp Ala Gln Thr Tyr Gly Cys Gln Asp Ile Ala Thr Gln Leu Val Asn

180 185 190

Asn Met Asp Ile Asp Val Ile Leu Gly Gly Gly Arg Met Tyr Met Phe

195 200 205

Pro Glu Gly Thr Pro Asp Pro Glu Tyr Pro Tyr Asp Val Asn Gln Thr

210 215 220

Gly Val Arg Lys Asp Lys Arg Asn Leu Val Gln Glu Trp Gln Ala Lys

225 230 235 240

His Gln Gly Ala Gln Tyr Val Trp Asn Arg Thr Glu Leu Leu Gln Ala

245 250 255

Ala Asn Asp Pro Ser Val Thr His Leu Met Gly Leu Phe Glu Pro Ala

260 265 270

Asp Met Lys Tyr Asn Val Gln Gln Asp Pro Thr Lys Asp Pro Thr Leu

275 280 285

Glu Glu Met Thr Glu Ala Ala Leu Gln Val Leu Ser Arg Asn Pro Gln

290 295 300

Gly Phe Tyr Leu Phe Val Glu Gly Gly Arg Ile Asp His Gly His His

305 310 315 320

Glu Gly Lys Ala Tyr Met Ala Leu Thr Asp Thr Val Met Phe Asp Asn

325 330 335

Ala Ile Ala Lys Ala Asn Glu Leu Thr Ser Glu Leu Asp Thr Leu Ile

340 345 350

Leu Ala Thr Ala Asp His Ser His Val Phe Ser Phe Gly Gly Tyr Thr

355 360 365

Leu Arg Gly Thr Ser Ile Phe Gly Leu Ala Pro Ser Lys Ala Ser Asp

370 375 380

Asn Lys Ser Tyr Thr Ser Ile Leu Tyr Gly Asn Gly Pro Gly Tyr Val

385 390 395 400

Leu Gly Gly Gly Leu Arg Pro Asp Val Asn Asp Ser Ile Ser Glu Asp

405 410 415

Pro Ser Tyr Arg Gln Gln Ala Ala Val Pro Leu Ser Ser Glu Ser His

420 425 430

Gly Gly Glu Asp Val Ala Val Phe Ala Arg Gly Pro Gln Ala His Leu

435 440 445

Val His Gly Val Gln Glu Glu Thr Phe Val Ala His Val Met Ala Phe

450 455 460

Ala Gly Cys Val Glu Pro Tyr Thr Asp Cys Asn Leu Pro Ala Pro Ser

465 470 475 480

Gly Leu Ser Asp Ala Ala His Leu Ala Ala Ser Pro Pro Ser Leu Ala

485 490 495

Leu Leu Ala Gly Ala Met Leu Leu Leu Leu Ala Pro Ala Leu Tyr

500 505 510

GCCAAGAATG TCATCCTC 18

GAGGATGACA TTCTTGGC 18

GGTGTAAGTG CAGCCGC 17

GCGGCTGCAC TTAGACC 17

AATGTACATG TTTCCTG 17

CAGGAAACAT GTACATT 17

›Example 4 · 4 of 4

CCAGGGCTTC TACCTCTT 18

AAGAGGTAGA AGCCCTGG 18

ACCAGAGCTA CCACCTCG 18

AAGCAGGAAA CCCCAAGA 18

CTTCAGTGGC TTGGGATT 18

AATCCCAAGC CACTGAAG 18

CGAGGTCGAC GGTATCG 17

GCAGGTCTCT CAGCTGGGAT GAGGGTGAGG 30

GCAGGTCTCA GCTGAGGAGG AAAACCCCGC 30

GCAGGTCTCT GTTGTGTCGC ACTGGTT 27

GGTCTCTTTC TTGGCCCGGT TGATCAC 27

GGTCTCAAGA AAGCAGGGAA GGCCGTC 27

GGTCTCGTGC ATCAGCAGGC AGGTCGGC 28

GGTCTCATGC ACAGAAGAAT GGCTGCCAG 29

GGTCTCAAAC ATGTACATTC GGCCTCCACC 30

GTCTCCATGT TTCCTGAGGG GACCCCA 27

GGTCTCCTGC CATTCCTGCA CCAGGTT 27

GGTCTCTGGC AGGCCAAGCA CCAGGGA 27

GGTCTCCAGG GTCGGGTCCT TGGTGTG 27

GGTCTCGACC CTGGCGGAGA TGACG 25

GGTCTCCTCA GTCAGTGCCA TATA 24

GGTCTCACTG AGGCGATCAT GTTTGAC 27

TGCACCAGGT GCGCCTGCGG GCC 23

GCCGCACAGC TGGTCTACAA CATGGAT 27

GCTGTCTAAG GCCTTGCCGG GGGC 24

GCCGCACAGC TGGTCTACAA CATGGAT 27

GGGGGTCTCG CTTGCTGCCA TTAAC 25

GTTAATGGTC TCACAAGCGA GGAACCCTCG 30

CCCGTGGGTC TCGCTAGCCA GGGGCAC 27

GTTAATGGTC TCACAAGCGA GGAACCCTCG 30

GATGCTGGTC TCGGTGGAGG GGGCTGGCAG 30

CTGCCAGGTC TCACCACCGC CACCAGCATC 30

CATACGATTT AGGTGACACT ATAG 24

GGTCTCTGGC AGGCCAAGCA CCAGGGA 27

GTAGAAGCCC CGGGGGTTCC TGCT 24

AGCAGGAACC CCCGGGGCTT CTAC 24

TGCCATATAA GCTTTGCCGT CATGGTG 27

GGTCTCTTTC TTGGCCCGGT TCATCAC 27

TGGTCACCAC TCCCACGGAC TTCCCTG 27

GGTCTCAAAC ATGTATTTTC GGCCTCCACC 30

GGTCTCATGT TTCCTGTGGG GACCCCAGAC 30

GGTCTCCTGC CATGCCTGCA CCAGGTT 27

3 of 10 part labels are ours — the grant heads the rest

Claims as granted

10 claims

Classifications

12 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C12N15/55
C12N1/21
C12N9/16
C12N1/19
C12N15/09
C12N1/15
C12N5/10

USPC · US Patent Classification

435/196530/350435/252.3435/320.1536/23.2

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.1 y

1,140 days filing → grant

Office actions

after a restriction

Responses

no RCE

Examiner

Ponnathapu Achutamurthy

art unit 1652 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 10 back · 16 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.